** Shares of drug developer BioAge Labs down ~70% to $6.13 premarket
** Brokerage Jefferies downgrades stock to "hold" from "buy"; lowers PT to $7 from $42
** New PT represents a 65.2% downside to Friday's close of $20.09
** Brokerage lowers PT on discontinuation of co's mid-stage obesity drug trial due to liver safety concerns
** Brokerage expects significant "stock drop"
** Brokerage also lowers co's drug pipeline value to $200 mln from $300 mln
** As of last close, stock has fallen 10.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。